Cryptocurrencies: 5,968
Markets: 542
Marketcap: $ 401.21 B
24h Vol: $ 45.63 B
BTC Dominance: 60.00%

Global market data

Cryptocurrencies: 5,968
Markets: 542
Marketcap: $ 401.21 B
24h Vol: $ 45.63 B
BTC Dominance: 60.00%

[ZEROHEDGE] Halted Trials Raise New Safety Questions About ‘Rushed’ COVID-19 Vaccines

Zero Hedge

Halted Trials Raise New Safety Questions About ‘Rushed’ COVID-19 Vaccines

Tyler Durden

Sat, 10/17/2020 – 11:31

In the interest of “transparency”, Pfizer CEO Dr. Albert Bourlas released a statement on Friday outlining the timeline for when its experimental COVID-19 vaccine might be ready for approval for regular, non-emergency use. Much to Trump’s chagrin, CEO Dr. Albert Bourla said the earlier the company expects to apply for an emergency-use approval from the FDA would be the third week of November, after the election has come and gone.

The news capped off what was a busy week for vaccine news, which started Monday night with reports that Phase 3 trials for Johnson & Johnson’s COVID-19 vaccine have been paused after a participant came down with an “unspecified” illness.

While JNJ executives insisted their vaccine candidate likely wasn’t the cause, they brought in investigators and are now working to get the trial going again as quickly as possible. If what happened with the AstraZeneca-Oxford vaccine is any guide, it could be weeks before US regulators sign off on allowing the trial to resume. AstraZeneca-Oxford trial in the US has been paused for more than a month.

Join our Telegram channels

Join our Telegram group ➡️ t.me/Liquidary

Follow us Twitter ➡️ twitter.com/liquidary

 

Find the full article here

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

Liquidary.com will use the information you provide on this form to be in touch with you and to provide updates and marketing. You can unsubscribe anytime.